Sep 09, 2018 - Sep 13, 2018
Salzburg, Austria
MSACL 2018 – September 9-13 | Salzburg, Austria

Previous MSACL events

MSACL Europe 2017

From proven clinical laboratory services and diagnostics to scalable translational research solutions, we are a partner you can trust who will help you efficiently develop and apply clinical applications today, and for many years into the future. Our portfolio of Chromatography and Mass Spectrometry solutions are designed to empower clinical laboratories around the world with flexible research to lab developed test solutions and fully automated diagnostic testing capabilities.

Check out our full lineup of products, workshops, and posters.


Wednesday, September 13, 8:15 – 8:45

Introducing the Thermo Scientific Cascadion SM Clinical Analyzer: Accuracy. Ease-of-Use. Designed for the Clinical Lab.

Presenter: Sarah Robinson, PhD, Market Development Specialist, Thermo Fisher Scientific

The Thermo Scientific Cascadion SM Clinical Analyzer is the first all-in-one LC-MS/MS solution designed to meet the needs of clinical laboratories. Our fresh vision for fully automated liquid chromatography-tandem mass spectrometry (LC-MS/MS) testing was cultivated by listening to our customers. You asked for a complete solution that was accurate, easy-to-use, and designed for the clinical laboratory. The Cascadion Clinical Analyzer is designed as a turnkey solution to enable clinical labs to easily adopt the power and capabilities of LC-MS/MS as the gold standard in diagnostic testing. The Cascadion system combines assays, software, accessories, consumables and support/service in a standalone system designed to meet the regulatory requirements for routine and specialized clinical testing. This presentation will showcase the Cascadion solution.

This product is in development and not yet available for sale. This product is not CE marked or FDA 510(k) cleared.

Wednesday, September 13, 16:00 – 16:30

Quantitation of endocrine markers using High Resolution Mass Spectrometry

Presenter: Laura Owen, University Hospital of South Manchester

Traditionally the quantitation of endocrine biomarkers has been performed using triple quadrupole analysers whereas orbitrap technology lends itself primarily to drug monitoring and screening applications. However, in recent years, orbitrap high resolution mass spectrometry systems have proved to be a great screening and quantitation tools.

Our research goal was to quantify renin activity, aldosterone and metanephrines using orbitrap high resolution Mass Spectrometry, in order to bring an added level of capability and flexibility to our lab. For plasma renin analysis, data was acquired in both PRM and full scan modes while, for aldosterone analysis, extract was analysed by PRM only with negative ion mode. Renin activity was measured at concentration level typically found in Conn’s syndrome with sufficient sensitivity. PRM showed slightly superior sensitivity than full scan mode. Metanephrine and normetanephrine both gave adequate sensitivity and calibration lines however 3-methoxytyramine was not sufficiently sensitive. Aldosterone demonstrated good sensitivity in sub 100 pmol/L concentrations.

The QE focus demonstrated its ability to quantify difficult to measure endocrine markers offering quantitation capabilities along with full scan thus bringing screening, protein discovery and quantitative capabilities to the clinical laboratory.

Posters and presentations


* For Research Use Only. Not for use in diagnostic procedures.


Join us at MSACL 2016 Europe | 12th – 15th September | Salzburg, Austria | Booths # 12-13

What you do in clinical research changes the world one life at a time

Welcome to the on-demand highlights from MSACL 2016 held in Salzburg, Austria, 13–15 September 2016. From the comfort of your desk, download our poster presentations and seminars from MSACL 2016.

Join the experience and hear expert testimonials and discover the latest developments in workflow automation, online sample preparation, and simplified data analysis to help solve your toughest analytical challenges


Microsampling techniques and LC-MS/MS: therapeutic drug monitoring research to help personalize medicine for our children

Giuliana Cangemi, PhD, MSC - Istituto Giannina Gaslini Children's Hospital in Genoa, Italy

Neonates, infants, and children undergo major and rapid age-related physiologic and biochemical changes, especially during the first year of life, resulting in different clinical pharmacokinetic (PK) and pharmacodynamic (PD) parameters compared to adults. Approximately 10% of all drugs prescribed are for children, making the majority of prescriptions off-label. Premature infants in neonatal intensive care units can receive up to twenty drugs during their hospital stay, and their blood often needs to be monitored by the laboratory. The availability of reliable analytical methods and microsampling techniques is thus crucial for therapeutic drug monitoring (TDM) and for conducting clinical PK studies in pediatrics, especially for low-birth-weight neonates. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is the analytical technique of choice, guaranteeing high specificity, accuracy, and reproducibility. Sensitivity is of fundamental importance, not only to limit blood sample volume, but also to simplify sample preparation procedures and improve throughput. In this context, alternative sampling strategies such as dried blood spot, volumetric microsampling devices, and dried plasma spot have an emerging role. This workshop will explore analytical challenges and opportunities and possible application to routine clinical analysis.

Speeding up the cancer biomarker discovery: Advanced Clinical Proteomics workflow with High Resolution MS

Sebastien Gallien, former researcher at CRP-Santé LIH Luxembourg Institute of Health, Thermo Fisher Scientific

Adoption of cancer biomarkers in clinical labs has been plagued by the speed with which these biomarkers are discovered and validated for clinical use. Clinical proteomics approaches where the use of predefined set of surrogate peptides for proteins has been helpful in systematically identifying these markers. Targeted analyses using parallel reaction monitoring (PRM), performed on high resolution and accurate-mass (HRAM) quadrupole-Orbitrap mass spectrometers, present the selectivity and sensitivity to confidently quantify peptides in complex samples. The internal standards (IS) used for isotope dilution quantification were recently leveraged to actually drive the acquisition (“internal standard triggered-parallel reaction monitoring”, IS-PRM), thus improving the acquisition efficiency. The application of this advanced PRM method was investigated for clinical proteomics, involving high-throughput screening and accurate quantification. Analyses of lung cancer markers in clinical plasma samples illustrating an advanced workflow automation and improved portability of the developed assays will be discussed in detail. Learn what it takes to uncover biomarkers faster for future use in predictive diagnostic.